BRIEF-Absci Announces First Participants Dosed In Phase 1 Clinical Trial Of Abs-101, A Potential Best-In-Class Anti-TL1a Antibody For The Treatment Of Inflammatory Bowel Disease

Reuters
14 May
BRIEF-Absci Announces First Participants Dosed In Phase 1 Clinical Trial Of Abs-101, A Potential Best-In-Class Anti-TL1a Antibody For The Treatment Of Inflammatory Bowel Disease

May 13 (Reuters) - Absci Corp ABSI.O:

  • ABSCI ANNOUNCES FIRST PARTICIPANTS DOSED IN PHASE 1 CLINICAL TRIAL OF ABS-101, A POTENTIAL BEST-IN-CLASS ANTI-TL1A ANTIBODY FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE

  • ABSCI CORP: INTERIM DATA ANTICIPATED IN SECOND HALF OF 2025

  • ABSCI CORP - ABS-101 SHOWS HIGH POTENCY AND QUARTERLY DOSING POTENTIAL

Source text: ID:nGNX5RX86F

Further company coverage: ABSI.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10